Meta-analysis of the therapeutic effects of various methods for the treatment of chronic atrial fibrillation

GANG LIN¹*, HUI-HE LU¹*, YI SHEN², JIAN-FEI HUANG¹, LIN-SHENG SHI¹ and YI-NAN GUO²

¹Cardiovascular Medical Department, The First People's Hospital of Nantong, Nantong, Jiangsu 226001; ²School of Public Health, Nantong University, Nantong, Jiangsu 226009, P.R. China

Received March 9, 2013; Accepted May 31, 2013

DOI: 10.3892/etm.2013.1158

Abstract. The aim of this study was to analyze the therapeutic effects of various methods for the treatment of chronic atrial fibrillation (AF). Randomized controlled trials (RCT) concerning drug therapy and catheter ablation for the treatment of chronic AF were retrieved. The RevMan 5.1 software package was used for the meta-analysis. A total of 20 papers were assessed in this study. The results of the analysis indicated that the success rate was lower [odds ratio (OR), 8.94; 95% confidence interval (CI), 4.70-17.02; P<0.0001] and the relapse rate was higher (OR, 0.07, 95% CI, 0.05-0.10; P<0.0001) for drug therapy compared with that for catheter ablation. With regard to different catheter ablation procedures, the success rate for pulmonary vein antrum isolation (PVAI) was lower compared with that for PVAI plus complex fractionated atrial electrogram (CFAE; OR, 0.53; 95% CI, 0.37-0.78; P<0.0001). Pulmonary vein isolation (PVI) plus left atrial ablation (LAA) had a higher success rate compared with PVI alone (OR, 2.79; 95% CI, 1.59-4.88, P=0.0003). There was not identified to be a significant difference in the success rates between PVAI and CFAE (OR, 2.05; 95% CI, 0.06-205.74; P=0.76) or between PVI and circumferential pulmonary vein isolation (CPVI; OR, 0.94; 95% CI, 0.29-3.00; P=0.91). All the funnel plots of publication bias were essentially symmetrical. In conclusion, the success rate was higher and the relapse rate was lower for catheter ablation compared with drug therapy. Among the different procedures of catheter ablation, there were no significant differences in success rate between two single procedures; however, the success rates were higher for the combined methods compared with those for the single methods.

Introduction

Atrial fibrillation (AF) is the most common tachyarrhythmia (1). The incidence of AF is 3-5% in individuals aged >65 years and 9% in individuals aged >80 years (2). The incidence of cerebral apoplexy and heart failure is increased in patients with AF since the heart atrium loses mechanical function with slow blood flow (3,4). AF is the strongest independent risk factor for cerebral apoplexy and heart failure; 15% of cerebral apoplexy and 30% of heart failure cases are associated with AF and the mortality rate of patients with AF is three times the mortality rate of patients with sinus rhythm (5). Compared with other types of AF, chronic persistent AF is more complex and is difficult to treat. According to the AF treatment guidelines produced by the American College of Cardiology, American Heart Association and European Society of Cardiology (ACC/AHA/ESC) in 2006, chronic AF is defined as AF that persistently exists following drug therapy or electroversion (6).

A great deal of attention has been paid to radiofrequency catheter ablation for the treatment of chronic AF. The relapse rate of radiofrequency catheter ablation is 20-60% in the treatment of chronic AF (7-9). At present, there is no standard radiofrequency catheter ablation method for the treatment of chronic AF. The main methods of radiofrequency catheter ablation for treating chronic AF include pulmonary vein isolation (PVI), pulmonary vein antrum isolation (PVAI), circumferential pulmonary vein isolation (CPVI), complex fractionated atrial electrogram (CFAE) and PVI plus left atrial ablation (LAA). There has been considerable debate about the treatment of chronic AF with drugs or radiofrequency catheter ablation.

In order to compare the therapeutic effects of drug therapy and radiofrequency catheter ablation, as well as compare different procedures of radiofrequency catheter ablation, papers published in China and elsewhere between January 1, 2002 and May 1, 2012 concerning the treatment of chronic AF with drug or radiofrequency catheter ablation were retrieved and then analyzed with the RevMan 5.1 software package. This study discusses different strategies for the treatment of chronic AF.

Materials and methods

Paper retrieval. Papers published in China and other countries between January 1, 2002 and May 1, 2012, which reported the success rates and relapse rates of drug therapy and catheter abla-
tion for the treatment of chronic AF were retrieved. Databases used were Chinese HowNet, VIP, Wanfang, Medline, Wiley, SpringerLink, Google Scholar and Science Direct.

The search items included the title, keyword and abstract. The following English search terms and the corresponding Chinese terms were used: atrial fibrillation, ablation/catheter ablation, drugs/anti-arrhythmia and chronic atrial fibrillation/permanent atrial fibrillation.

Inclusion and exclusion criteria. Inclusion criteria were as follows: i) papers published in China and other countries between January 1, 2002 and May 1, 2012; ii) randomized controlled trials (RCTs); iii) patients with chronic AF; iv) clear diagnostic criteria: drugs did not effectively maintain sinus rhythm or persistent AF for >7 days repeated within 6 months; v) data collection with a scientific method; vi) data analysis with a correct and scientific method; vii) interventions including radiofrequency catheter ablation and drug therapy; and viii) only one paper selected from several papers about the same population. Exclusion criteria were as follows: i) non-RCT; ii) data collection with a non-scientific method; iii) data analysis with non-scientific method; iv) literature reviews and v) repeated papers.

Quality evaluation. The quality of papers was evaluated according to the quality evaluation criteria described in v.4.2.2 of the Cochrane System Assessment handbook. The quality of papers was divided into grades A, B and C based on the randomized method, hidden method, double-blind method, loss of follow-up and exodus of patients from the study. Grade A had low bias and the lowest possibility of bias, and completely conformed to the four quality standards. The four quality standards include randomized method, hidden method, double-blind method, and loss of follow-up and exodus of patients. Grade B had moderate bias and a moderate possibility of bias, and partially conformed to ≥1 quality standards. Grade C had high bias and a high possibility of bias, and did not conform to ≥1 quality standards completely.

Statistical analysis. According to the requirements of the meta-analysis, data processing was performed and a database was established. Data analysis was performed with the RevMan 5.1 software package. The therapeutic effects of catheter ablation and drug therapy for chronic AF were analyzed, with the odds ratio (OR) as an effective index, and the OR and 95% confidence interval (CI) were calculated. Specific steps were as follows: i) OR served as the summary statistic; ii) an homogeneity test was performed using the χ² test. If P>0.1, multiple independent studies had homogeneity and OR was calculated with the fixed effect model. If P≤0.1, multiple independent studies had heterogeneity and after sensitivity or stratified analyses, the data had homogeneity; then OR was calculated with the fixed effect model. Otherwise OR was calculated with the random effect model; iii) the probability value of the summary statistic was first obtained with the U test. If P≤0.05 was considered to indicate a statistically significant difference; iv) the publication bias was identified with funnel plots. The funnel plots were generated by the RevMan 5.1 software package, with OR values as the x-axis and with SE (log OR) as the y-axis. The publication bias was evaluated by observing whether the funnel plot was symmetrical.

Results

Paper retrieval. A total of 20 papers (10-29) were used in this study. Of the 20 papers, eight compared drug therapy with radiofrequency catheter ablation; five compared PVAI and PVAI + CFAE, of which two papers also compared PVAI alone and CFAE alone; four compared PV1 + LAA and PV1; and three compared PV1 and CPVI (Table I).

Comparison of success rates between catheter ablation and drug therapy. There were eight papers (10-17) that compared the success rates of catheter ablation and drug therapy. These papers included a total of 951 patients, with catheter ablation as the test group and drug therapy as the control group (Table II).

In the eight papers, there were 476 patients in the test group and 475 patients in the control group. The homogeneity test (χ²=30.58, v=7, P<0.0001) demonstrated that the eight papers had heterogeneity; therefore, the random effect model was adopted. The OR value was 8.94 (95% CI, 4.70-17.02; z=6.68; P<0.0001), suggesting that the success rate was significantly higher for catheter ablation compared with that for drug therapy (Fig. 1).

Comparison of relapse rates between catheter ablation and drug therapy for treatment of chronic AF. There were seven papers (10,11,13-17) that compared the relapse rates of catheter ablation and drug therapy for treatment of chronic AF. The seven papers included a total of 753 patients, with catheter ablation as the test group and drug therapy as the control group (Table III).

In the seven papers, there were 377 patients in the test group and 376 patients in the control group. The homogeneity test (χ²=5.87, v=6, P=0.44, P>0.10) demonstrated that the seven papers had homogeneity; therefore, the fixed effect model was adopted. The OR value was 0.07 (95% CI, 0.05-0.10; z=14.06; P<0.0001), suggesting that the relapse rate was significantly lower for catheter ablation compared with that for drug therapy (Fig. 2).

Comparison of success rates between PVAI and CFAE. There were two papers (18,19) comparing the success rates of PVAI and CFAE for treatment of chronic AF. The two papers included a total of 128 patients, with PVAI as the test group and CFAE as the control group (Table I).

In the two papers, there were 70 patients in the test group and 58 patients in the control group. The homogeneity test (χ²=28.47, v=1, P=0.0000, P<0.10) demonstrated that the two papers did not have homogeneity; therefore, the random effect model was adopted. The OR value was 2.05 (95% CI, 0.06-205.74; z=0.30; P=0.76), suggesting that there was no significant difference in success rates between PVAI and CFAE for treatment of chronic AF (Fig. 3).

Comparison of success rates between PVAI and PVAI + CFAE. There were five papers (18-22) comparing the success rates of PVAI and PVAI + CFAE for treatment of chronic AF. The five papers included a total of 559 patients,
| No. (ref.) | Publication date (year) | First author               | Title of paper                                                                                                                                 |
|-----------|-------------------------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| 1 (10)    | 2010                    | David J. Wilber            | Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial |
| 2 (11)    | 2006                    | Carlo Pappone              | A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF study |
| 3 (12)    | 2011                    | Carlo Pappone              | Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study           |
| 4 (13)    | 2003                    | R. Krittayaphong           | A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation |
| 5 (14)    | 2009                    | Giovanni B. Forleo         | Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy |
| 6 (15)    | 2008                    | Pierre Jaïs                | Catheter ablation versus anti-arrhythmic drugs for atrial fibrillation: the A4 study                                                          |
| 7 (16)    | 2006                    | Hakan Oral                | Circumferential pulmonary-vein ablation for chronic atrial fibrillation                                                                        |
| 8 (17)    | 2006                    | Giuseppe Stabile          | Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study) |
| 9 (18)    | 2009                    | Luigi Di Biase             | Atrial fibrillation ablation strategies for paroxysmal patients: randomized comparison between different techniques                              |
| 10 (19)   | 2011                    | Minglong Chen             | Randomized comparison between pulmonary vein antral isolation versus complex fractionated electrogram ablation for paroxysmal atrial fibrillation |
| 11 (20)   | 2008                    | Claude S. Elayi            | Ablation for longstanding permanent atrial fibrillation: results from a randomized study comparing three different strategies                |
| 12 (21)   | 2009                    | Hakan Oral                | A randomized assessment of the incremental role of ablation of complex fractionated atrial electrograms after antral pulmonary vein isolation for long-lasting persistent atrial fibrillation |
| 13 (22)   | 2007                    | Atul Verma                | Efficacy of adjuvant anterior left atrial ablation during intracardiac echocardiography-guided pulmonary vein antrum isolation for atrial fibrillation |
| 14 (23)   | 2006                    | Stephan Willems           | Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison |
| 15 (24)   | 2005                    | Mélèze Hocini             | Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study |
| 16 (25)   | 2004                    | Michel Haïssaguerre        | Changes in atrial fibrillation cycle length and inducibility during catheter ablation and their relation to outcome                           |
| 17 (26)   | 2006                    | Imran Sheikh              | Pulmonary vein isolation and linear lesions in atrial fibrillation ablation                                                                |
with PVAI as the test group and PVAI + CFAE as the control group (Table V).

In the five papers, there were 268 patients in the test group and 291 patients in the control group. The homogeneity test ($\chi^2=5.98$, $v=4$, $P=0.20$, $P>0.10$) demonstrated that the papers had homogeneity; therefore, the fixed effect model was adopted. The OR value was 0.53 (95% CI, 0.37-0.78; $z=3.23$; $P=0.001$), suggesting that the success rate for treatment of chronic AF was significantly higher for PVAI + CFAE than for PVAI (Fig. 4).

Comparison of success rates between PVI and PVI + LAA.

There were four papers (23-26) in which the success rates of PVI and PVI + LAA in the treatment of chronic AF were compared. These papers included a total of 322 patients, with PVI + LAA as the test group and PVI as the control group (Table VI).

In the four papers, there were 162 patients in the test group and 160 patients in the control group. The homogeneity test ($\chi^2=2.71$, $v=3$, $P=0.44$, $P>0.10$) demonstrated that the papers had homogeneity; therefore, the fixed effect model was adopted. The OR value was 2.79 (95% CI, 1.59-4.88; $z=3.59$;
suggesting that the success rate was significantly higher for PVI + LAA compared with that for PVI (Fig. 5).

Comparison of success rates between PVI and CPVI. There were three papers (27-29) in which the success rates of PVI and CPVI were compared. The three papers included a total of 310 patients, with PVI as the test group and CPVI as the control group (Table VII).

In the three papers, there were 150 patients in the test group and 160 patients in the control group. The homogeneity test
\( \chi^2 = 12.82, v=2, P=0.002, P<0.10 \) demonstrated that the papers did not have homogeneity; therefore, the random effect model was adopted. The OR value was 0.94 (95% CI, 0.29 -3.00; \( z=0.11; P=0.91 \)), suggesting that there were no significant differences in the success rates between PVI and CPVI for treatment of chronic AF (Fig. 6).
Publication bias. All funnel plots comparing the success rates of catheter ablation and drug therapy, PVAI and CFAE, PVAI and PVAI + CFAE, PVI + LAA and PVI, and PVI and CPVI were essentially symmetrical, and the majority of the points were located within the 95% CI. The funnel plot comparing the relapse rates of catheter ablation and drug therapy was essentially symmetrical and the majority of the points were located within the 95% CI.

Discussion

In this study, a meta-analysis of catheter ablation and drug therapy for the treatment of chronic AF was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The results indicated that for the treatment of chronic AF, the success rate is higher and the relapse rate is lower for catheter ablation compared with that for drug therapy. There were no significant differences between the success rates of PVAI and CFAE, and PVI and CPVI; however, the success rates were higher for PVAI + CFAE compared with that for PVAI, and for PVI + LAA compared with that for PVI. The results of publication bias indicated that the results of the meta-analysis were stable and reliable, truly reflecting the status of catheter ablation and drug treatment of chronic AF.

AF treatment includes rate control and rhythm control. Although it has been reported that rate control is a reasonable choice for the treatment of AF (30), rate control alone does not reduce the risk of cerebral apoplexy and improve atrioventricular synchrony. Antithrombotic therapy with warfarin decreases the incidence of cerebral apoplexy and reduces the mortality rate; however, there is the risk of bleeding, which requires long-term monitoring of international normalized ratio (INR) of prothrombin time with low patient compliance. Compared with rate control, rhythm control decreases the mortality rate and the incidence of transient ischemic attack (TIA), cerebral infarction (31), systemic embolism, hemorrhage and heart failure (32). Therefore, rhythm control is likely to be more effective than rate control. The conventional methods of rhythm control include anti-arrhythmic drugs, direct current countershock and the surgical maze procedure. However, these methods are limited in clinical practice due to their therapeutic effects and safety. In the past 20 years, a great deal of attention has been paid to catheter ablation for the treatment of AF. In the AF treatment guidelines established by ACC/AHA/ESC in 2008, catheter ablation is suitable for patients who exhibit no therapeutic effects following treatment with class I or III anti-arrhythmic drugs, are unable to tolerate the side-effects of drugs or have symptomatic heart failure or low cardiac output prior to the use of anti-arrhythmic drugs.

The pathogenesis of AF is not completely clear. At present, its mechanism mainly includes triggering factors and an electrical substrate (or atrial substrate). The majority of the triggering factors are located in the pulmonary veins and superior vena cava; however, a few triggering factors are located in the crista terminalis, coronary sinus, Marshall ligaments and atrial posterior wall. Triggering factors are also called triggering foci. Electrical substrate refers to the changes in electrophysiological characteristics to maintain AF and mainly includes electrical reconstitution, anatomical reconstitution, reconstitution of autonomic nerves and reconstitution of the renin-angiotensin system. Atrial dilatation, myocarditis, myocardial fibrosis and increased autonomic nervous tension all serve as triggering factors and/or an electrical substrate to lead to AF. Triggering factors and the electrical substrate may be located in the same place or at different locations. Radiofrequency ablation is used to treat AF through the isolation of triggering factors and interference with the electrical substrate (33,34).
The limitations of the current study are that only a small number of papers were included in the study, unpublished papers from conferences were not included and the quality control standards were not uniformly applied. Future meta-analyses should include a greater number of RCTs.

Our results suggest that catheter ablation is more effective than drug therapy in the treatment of AF. There are no significant differences in success rates between two single procedures for catheter ablation; however, the success rate is higher in PVAI + CFAE compared with that in PVAI, and in PVI + LAA compared with that in PVI.

References

1. Furb erg CD, Psaty BM, Manolio TA, et al: Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 74: 236-241, 1994.
2. Kannel WB, Wolf PA, Benjamin EJ and Levy D: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82: 2N-9N, 1998.
3. Singer DE: Overview of the randomized trials to prevent stroke in atrial fibrillation. Ann Epidemiol 3: 563-567, 1993.
4. Kazemian P, Oudit G and Jugdhit BI: Atrial fibrillation and heart failure in the elderly. Heart Fail Rev 17: 597-613, 2012.
5. Fuster V, Rydén LE, Cannom DS, et al: ACC/AHA/ESC 2006 Guidelines for the Management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 57: e101-e198, 2011.
6. Fuster V, Rydén LE, Cannom DS, et al: ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257-e354, 2006.
7. Joshi S, Choi AD, Kamath GS, et al: Prevalence, predictors, and prognosis of atrial fibrillation early after pulmonary vein isolation: findings from 3 months of continuous automatic ECG loop monitoring. J Am Coll Cardiol 52: 1089-1094, 2008.
8. Takahashi Y, Takahashi A, Kuwahara T, et al: Clinical characteristics of patients with persistent atrial fibrillation successfully treated by left atrial ablation. Circ Arrhythm Electrophysiol 3: 465-471, 2010.
9. Li C, Ding X, Zhang J, et al: Does the E/e′ index predict the maintenance of sinus rhythm after catheter ablation of atrial fibrillation? Echocardiography 27: 630-636, 2010.
10. Wilber DJ, Pappone C, Neužil P, et al: Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 303: 333-340, 2010.
11. Pappone C, Augello G, Sala S, et al: A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APFAB study. J Am Coll Cardiol 11: 2340-2347, 2006.
12. Pappone C, Vicedomini G, Augello G, et al: Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APFAB study. Circ Arrhythm Electrophysiol 4: 808-814, 2011.
13. Krittayaphong R, Raungrattanamorn O, Bhuripanyo K, et al: A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J Med Assoc Thai 86 (Suppl 1): S8-S16, 2003.
14. Forleo GB, Mantica M, De Luca L, et al: Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 20: 22-28, 2009.
15. Jaïs P, Cauchemez B, Macle L, et al: Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 118: 2498-2505, 2008.
16. Ghi H, Pappone C, Chugh A, et al: Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2: 934-941, 2006.
17. Stabile G, Bertaglia E, Senatore G, et al: Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 27: 216-221, 2006.
18. Di Biase L, Elayi CS, Fahmy TS, et al: Atrial fibrillation ablation strategies for paroxysmal patients: randomized comparison between different techniques. Circ Arrhythm Electrophysiol 42: 113-120, 2009.
19. Chen M, Yang B, Chen H, et al: Randomized comparison between pulmonary vein antral isolation versus complex fractionated electrogram ablation for paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 22: 973-981, 2011.
20. Elayi CS, Verma A, Di Biase L, et al: Ablation for longstanding persistent atrial fibrillation: results from a randomized study comparing three different strategies. Heart Rhythm 5: 1658-1664, 2008.
21. Oral H, Chugh A, Yoshida K, et al: A randomized assessment of the incremental role of ablation of complex fractionated atrial electrograms after ablation of the pulmonary veins for long-lasting persistent atrial fibrillation. J Am Coll Cardiol 53: 782-789, 2009.
22. Verma A, Patel D, Famy T, et al: Efficacy of adjunct anterior left atrial ablation during intracardiac echocardiography-guided pulmonary vein antral isolation for atrial fibrillation: a prospective randomized controlled trial. J Cardiovasc Electrophysiol 18: 151-156, 2007.
23. Willems S, Klemm H, Rostock T, et al: Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison. Eur Heart J 27: 2871-2878, 2006.
24. Hocini M, Jaïs P, Sanders P, et al: Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study. Circulation 112: 3688-3696, 2005.
25. Haïssaguerre M, Sanders P, Hocini M, et al: Changes in atrial fibrillation cycle length and inducibility during catheter ablation and their relation to outcome. Circulation 109: 3007-3013, 2004.
26. Sheikh I, Krum D, Cooley R, et al: Pulmonary vein isolation and linear lesions in atrial fibrillation ablation. J Interv Card Electrophysiol 17: 103-109, 2006.
27. Fiala M, Chovancik J, Nevrálová R, et al: Pulmonary vein isolation using segmental versus electroanatomical circumferential ablation for paroxysmal atrial fibrillation: over 3-year results of a prospective randomized study. J Interv Card Electrophysiol 22: 13-21, 2008.
28. Karch MR, Zrenner B, Deisenhofer I, et al: Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation 111: 2875-2880, 2005.
29. Nilsson B, Chen X, Pehrson S, et al: Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extrastial ablation strategy. Am Heart J 152: 537-538, 2006.
30. Chung MK, Shemanski L, Sherman DG, et al: Functional status in rate-versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll of Cardiol 46: 1891-1899, 2005.
31. Reynolds MR, Gunnarsson CL, Hunter TD, et al: Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a propensity-matched analysis. Circ Cardiovasc Qual Outcomes 5: 171-181, 2012.
32. Ogawa S, Yamashita T, Yamazaki T, et al: Atrial fibrillation ablation: is ostial pulmonary vein antral isolation versus complex fractionated electrocardiogram ablation for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 4: 242-248, 2011.
33. Tan HW, Wang XH, Shi HF, et al: Left atrial wall thickness: anatomic aspects relevant to catheter ablation of atrial fibrillation. Chin Med J (Engl) 125: 12-15, 2012.
34. Hunter RJ, Liu Y, Lu Y, et al: Left atrial wall stress distribution and its relationship to electrophysiologic remodeling in persistent atrial fibrillation. Circ Arrhythm Electrophysiol 5: 351-360, 2012.